Common complaints about Newself services

1. Customer experience: billing, cancellations and support breakdowns

A significant thread in user reviews centers on difficulty cancelling subscriptions, getting timely help, and account-access frustration—issues raised repeatedly in consumer review snippets where customers report trouble cancelling and recent replies from the company apologizing for access problems ^[1]. While some Trustpilot entries note quick remediation and on-time chilled deliveries, the presence of "a boatload of horrible well-earned reviews" in the review feed suggests recurring operational pain points rather than isolated incidents ^[1].

2. Transparency and trust: mixed automated signals about the website

Independent site-checkers give conflicting impressions: Scamadviser’s automated scan flagged language indicating the site may be incomplete or contain wording often linked to fraudulent activity and thus assigned a middling trust score, while cautioning readers to do manual due diligence ^[2]. By contrast, a Gridinsoft security analysis returned a perfect trust score and called the domain safe, illustrating how different automated tools and heuristics can produce opposite risk assessments for the same domain ^[5]. That divergence helps explain why consumers may feel uncertain: technical security looks good in at least one scan, but wording and site signals triggered warnings in another ^{[2] [5]}.

3. Medical expectations vs. platform reality: prescriptions are not guaranteed

NewSelf’s own legal and marketing copy explicitly positions the company as a technology platform that "collaborates with independent healthcare professionals" and warns that payment does not guarantee a prescription or that medication will be dispensed, a fine-print caveat that can clash with user expectations shaped by promotional language ^[3]. Critics point to this mismatch as a frequent complaint: customers who expect direct pharmacy service or guaranteed prescriptions can feel misled when clinicians decline to prescribe or when the platform routes care through affiliated providers ^{[3] [6]}. AllyRx’s expert review also highlights pricing and "fine-print risks" that buyers should weigh before purchasing GLP-1 related services through intermediaries ^[4].

4. Pricing, shipping and product-quality gripes — and some praise

Pricing is an explicit focal point for scrutiny: AllyRx lists price points (for example, $199 for semaglutide and $449 for tirzepatide) and flags who those price levels may suit while noting policy and shipping details customers should read closely ^[4]. User reviews present a split picture—some customers praise fast, chilled shipments and easy ordering, while others complain about order hiccups and unresolved problems that required company intervention, indicating inconsistent fulfillment experiences ^{[1] [4]}.

5. App and tech problems: bugs, feature gaps and therapist workflows

The Newself client app is promoted as a mental-health and scheduling tool and its App Store listing documents past bug fixes and feature updates (for example, basket persistence and booking features), which implies the company is iterating but also that users have experienced functionality issues ^[7]. On the provider side, NewSelf offers tools for clinicians — including the ability to pause availability — which suggests the platform is built for flexible provider workflows, but that flexibility could translate into variable patient availability that customers may interpret as service gaps ^[8].

6. Who benefits, hidden agendas and reporting limits

Marketing copy touts affordability and access to GLP medications while simultaneously disavowing affiliation with brand manufacturers, an approach that promotes uptake but also shields the company from responsibility when prescriptions aren’t issued ^[3]. Automated trust scores and user reviews shape public perception but carry their own biases: Scamadviser’s scan is automated and recommends manual checking, and Trustpilot entries can aggregate extremes that skew impressions ^{[2] [1]}. Reporting here is limited by the sources available: there are expert price/policy summaries and customer reviews but no regulatory enforcement records or comprehensive complaint-aggregation data in the provided materials, so systemic conclusions about safety or legality cannot be made from these sources alone ^{[4] [1] [2]}.